AP -- NEW YORK - Biotechnology company Genentech Inc. ended several studies combining its cancer drug Avastin and Pfizer Inc.'s Sutent because several patients developed a type of anemia. On Monday, the Food and Drug Administration issued a warning after patients in a study taking the drug combination in a midstage study developed the condition. The alert comes after Genentech (nyse: DNA - news - people ) informed health care professionals of several cases where certain patients in a midstage study had microangiopathic hemolytic anemia, which involves a loss of red blood cells.
